COMPANY
Immunocodex
Immunocodex is developing lipid nanoparticle mRNA-based therapies designed to induce antigen-specific immune tolerance. From company website Source · checked 2026-10-19
Sources for this description (1)
- Immunocodex is developing lipid nanoparticle mRNA-based therapies designed to induce antigen-specific immune tolerance.
- “We are pioneering the development of innovative lipid nanoparticle mRNA-based therapies designed to induce antigen-specific immune tolerance.” https://www.immunocodex.com/about-us (2026-10-19)